News | August 23, 2011

nContact Gains CE Mark for Fourth-Generation Epicardial Ablation System

August 23, 2011 — nContact Inc. has received CE Mark approval for the EPi-Sense Guided Coagulation Device with VisiTrax for the treatment of cardiac arrhythmias, including atrial fibrillation (AF). The EPi-Sense features epicardial sensing electrodes designed to allow both electrophysiologists (EP) and cardiothoracic surgeons to map and navigate the epicardium and locate areas for linear epicardial ablation.

The device further enhances the advantages of the Convergent Procedure, a closed chest, endoscopic technique enabled by nContact's Numeris Coagulation System with Visitrax. One procedural advantage includes visible access to the atrium posterior through a trans-diaphragmatic pericardial window (eliminating the need for chest incisions, ports, lung deflation or heart dissections). The device gives the ability to create visible, non-conductive, linear lesions on a beating heart. Also, EP mapping systems can now locate the device in real time.

Additionally, the new embedded electrodes indicate when the device is in contact with cardiac tissue. Consistent tissue contact assures the device is directed into the heart and avoids collateral tissue damage often associated with endocardial catheter ablation (where energy is directed outward from the atrium).

Prof. Borut Gersak, M.D., Ph.D., chief of department of cardiovascular surgery at University Medical Center, Ljubljana, Slovenia, commented, "The recently CE Mark-approved EPi-Sense with the addition of sensing electrodes is innovative and will be instrumental in allowing access to difficult areas of the heart, while improving ease of use for physicians and safety for patients. This technology in combination with the company's unique closed chest cardiac access, or SUBTLE (sub-thoracic, totalendoscopic) approach, is obsoleting invasive bi-lateral thorascopic technologies, which are poorly designed for true minimally invasive ablation procedures."

Paul Mounsey, BM, BCh, Ph.D., director of cardiac electrophysiology and pacing, University of North Carolina commented on the hybrid nature of the new device, "The EPi-Sense is the first epicardial device that can be used by both EPs and surgeons to ablate epicardially utilizing sensors that allow electrical mapping. Today, surgeons utilize the device to access and ablate the left atrium. Soon, European studies will be underway that utilize the EPi-Sense to access the ventricle. I suspect this device may quickly become a necessary part of the EP toolbox to better access epicardial areas not easily ablatable endocardially."

The Epi-Sense System is scheduled to be commercially available throughout Europe in the fourth quarter of 2011. It is currently not available in the United States.

For more information: www.ncontactinc.eu

Related Content

Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Technavio Projects 9 Percent Global Growth for Electrophysiology Therapeutic Devices

Image courtesy of Technavio

News | EP Lab| September 11, 2017
September 11, 2017 — According to the latest market study released by Technavio, the global...
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
CASTLE-AF Study shows Catheter Ablation of Atrial Fibrillation is First-Line Treatment for Heart Failure Patients. Biotronic Ilivia 7 ICD.

The CASTLE-AF Study shows catheter alation of AF can be used effectively to treat heart failure in patients with an implanted ICD.

News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause
Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices

Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices.

Feature | EP Lab| August 29, 2017 | Dave Fornell
August 29, 2017 — The U.S.
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Merge Hemo cath lab hemodynamics monitoring system.

Hemodynamic data shown on screens from the Merge Hemo recording system. It is among the newer generation hemodynamic systems for cath labs that are more user friendly and have technologies to speed workflow.

Feature | Hemodynamic Monitoring Systems| August 03, 2017 | Dave Fornell
The current generation of...
Overlay Init